Agios Pharmaceuticals (AGIO) Q2 2025 earnings summary

Executive summary

• Q2 2025 PYRUKYND net revenue reached $12.5 million, up 45% year-over-year and 44% sequentially, with strong pipeline progress and a robust cash position of $1.3 billion supporting launches and R&D.

• Net loss for Q2 2025 was $112.0 million, and for the first half of 2025, $201.3 million, reflecting increased R&D and SG&A expenses for clinical and commercial expansion.

• Multiple regulatory submissions for PYRUKYND in thalassemia are under review in the US, EU, and Middle East, with a PDUFA goal date of September 7, 2025.

• Announced commercialization partnerships in Europe (Avanzanite) and GCC, with ex-U.S. launches progressing.

• First patient dosed in tebapivat Phase 2 SCD trial and IND clearance for AG-236.

Financial highlights

• Q2 2025 net revenue was $12.5 million (up from $8.6 million in Q2 2024), and $21.2 million for the first half of 2025 (up from $16.8 million year-over-year), driven by PYRUKYND sales.

• Cost of sales for Q2 2025 was $1.7 million; gross margin for Q2 was approximately 86%.

• R&D expenses rose to $91.9 million in Q2 2025, including a $10 million milestone payment for AG-236.

• SG&A expenses increased to $45.9 million in Q2 2025, reflecting commercial launch preparations.

• Cash, cash equivalents, and marketable securities totaled $1.3 billion at June 30, 2025, down from $1.5 billion at year-end 2024.

Outlook and guidance

• PYRUKYND U.S. FDA PDUFA goal date for thalassemia is September 7, 2025, with potential EU approval in early 2026.

• Topline data for the RISE UP Phase 3 SCD trial expected by year-end 2025, with a possible U.S. launch in 2026.

• Cash position expected to fund operations and pipeline expansion for at least the next twelve months.

• Modest full-year net revenue growth expected for 2025, with Q4 reflecting partial thalassemia demand post-anticipated FDA approval.

• Continued quarter-on-quarter revenue variability anticipated due to ordering patterns and launch timing.